Valuation: Takeda Pharmaceutical Company Limited

Market Cap 8,402B 266B 51.7B 45.44B 42.13B 38.75B 73.16B 4,944B 74.78B 498B 196B 2,428B 194B 190B P/E 2027 *
43.2x
P/E 2028 * 27.7x
Enterprise Value 12,287B 389B 75.62B 66.45B 61.62B 56.67B 107B 7,231B 109B 729B 287B 3,551B 284B 278B EV / Sales 2027 *
2.65x
EV / Sales 2028 * 2.59x
Free-Float
99.26%
Yield 2027 *
3.84%
Yield 2028 * 3.92%
1 day+7.86%
1 month+7.86%
3 months-11.77%
6 months-5.31%
Current year-1.01%
1 month 82
Extreme 82
82.32
Current year 76.32
Extreme 76.32
95.3
1 year 70.8
Extreme 70.8
95.3
3 years 66.46
Extreme 66.46
95.3
5 years 66.1
Extreme 66.1
95.3
10 years 66.1
Extreme 66.1
95.3
Manager TitleAgeSince
Chief Executive Officer - 2026-06-23
Director of Finance/CFO 48 2024-03-31
Chief Tech/Sci/R&D Officer 47 2022-01-31
Director TitleAgeSince
Director/Board Member 73 2018-12-31
Director/Board Member 63 2026-06-23
Director/Board Member 62 2022-05-31
Change 5-day change 1-year change 3-year change Capi.($)
+7.86%-.--% - - 52.42B
-0.56%-2.64%+49.04%+168.24% 1,060B
+0.31%-2.00%+64.29%+63.06% 619B
-0.03%-5.01%+28.86%+83.73% 438B
-1.75%-2.91%+28.78%+24.35% 333B
+0.24%-2.61%+29.46%+46.50% 282B
-1.75%-12.77%+20.67%+23.05% 267B
+0.67%-0.76%-26.10%-37.25% 218B
-0.81%-3.66%+22.07%+59.72% 196B
+1.21%+0.10%+19.85%+72.03% 161B
Average +0.66%-3.33%+26.32%+55.94% 397.1B
Weighted average by Cap. +0.13%-3.10%+36.27%+82.99%

Financials

2027 *2028 *
Net sales 4,630B 146B 28.49B 25.04B 23.22B 21.35B 40.32B 2,725B 41.21B 275B 108B 1,338B 107B 105B 4,701B 149B 28.93B 25.42B 23.57B 21.68B 40.93B 2,766B 41.84B 279B 110B 1,359B 109B 106B
Net income 184B 5.81B 1.13B 995M 922M 848M 1.6B 108B 1.64B 10.91B 4.29B 53.15B 4.25B 4.16B 309B 9.78B 1.9B 1.67B 1.55B 1.43B 2.69B 182B 2.75B 18.35B 7.22B 89.4B 7.15B 6.99B
Net Debt 3,886B 123B 23.91B 21.01B 19.49B 17.92B 33.84B 2,287B 34.58B 231B 90.73B 1,123B 89.77B 87.86B 3,750B 119B 23.08B 20.28B 18.81B 17.3B 32.66B 2,207B 33.38B 223B 87.57B 1,084B 86.65B 84.81B
Logo Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the research, development, manufacturing and global sales of a wide range of pharmaceuticals. Its main business areas are divided into six, including gastroenterology, rare diseases, plasma-derived therapies, oncology (cancer), vaccines, and neuroscience (neuropsychiatric disorders). In research and development, the Company focuses on three priority disease areas, including gastroenterology and inflammatory diseases, neuroscience, and oncology, and also focuses on plasma-derived therapies.
Employees
47,029
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
5,318.00JPY
Average target price
6,106.87JPY
Spread / Average Target
+14.83%

Quarterly revenue - Rate of surprise